UConn | November 20, 2020
Consistent assembling has just begun to override customary group handling in the domain of tablet creation. The following region due for an assembling update? Nanoparticle drug conveyance frameworks, one startup thinks—and it's currently prepared to pitch its foundation to drugmakers.
The University of Connecticut as of late authorized its ceaseless nanoparticle fabricating innovation to DIANT Pharma, a startup helped to establish by the stage's designers Antonio Costa, Ph.D., and Diane Burgess, Ph.D.
The high-throughput framework can possibly spare tidy up room space, bring down the quantity of preparing steps and diminish the quantity of bunches created every year. Since the stage is persistent, it should empower makers to hop in the event that anything turns out badly, redirecting or eliminating just a little bit of the item instead of rejecting a whole group, Costa, CEO at DIANT and partner research teacher at UConn, said in a meeting.
Prnewswire | August 18, 2020
Managing occasional stress and keeping a calm mind are vital for navigating today's world. And USANA's new Mood and Relaxation product line is designed to help. The company's annual Americas and Europe Convention went virtual this year, and USANA continued to impress with the launch of its new Stress Relief mood-support supplement and Calm Response essential oil balm. These products take a natural and mindful approach to overall health and well-being.* To find out more about USANA and its new Mood and Relaxation product line, please visit usana.com. "The launch of our new product line marks a pivotal moment in USANA's history," says Dan Macuga, USANA's chief communications and marketing officer. "We are expanding our reach into a new market space, and the quality of our new products prove it's a space we belong. Day-to-day stressors and obstacles can be overwhelming, and I'm proud USANA has formulated products to help our customers maintain positive emotional health."
Yiling Pharmaceutical Co | September 19, 2020
Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter referred to as the "FDA"), which were submitted by Yiling Wanzhou International Pharmaceutical Co., Ltd., one of the wholly-owned subsidiaries of Yiling Pharmaceutical Co., Ltd., meaning that these products are approved to be produced and sold in the U.S. market. The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United States in 1988. Currently its licensed producer is Alvogen Malta Operations Ltd., and the major manufacturers of its generic drugs are Casi, Ascent, and etc. in the United States. In addition to the originally researched and developed drugs, there are 11 producers for the generic drugs in China, among which, only one has passed the consistency evaluation. According to the IMS database, the saleroom of Lisinopril Tablets was about USD 131.39 million in the U.S. market in 2019.